UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 4, 2005
DRAGON PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
Florida 0-27937 65-0142474
------- ------- ----------
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
1055 Hastings Street, Suite 1900
Vancouver, British Columbia V6E 2E9
---------------------------- -------
(Address of Principal Executive Offices) (Zip Code)
(604) 669-8817
--------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 7 - Regulation FD
-------------------------
Item 7.01 Regulation FD Disclosure
Dragon Pharmaceutical Inc. announced its business update after the
completion of acquisition of Oriental Wave and selected unaudited 2004 pro-forma
combined financial data on the attached press release.
Section 9 - Financial Statements and Exhibits
---------------------------------------------
Item 9.01 Financial Statements and Exhibits
Exhibit No. Exhibit Description
---------- -------------------
99 Press release announcing business update after the
completion of acquisition of Oriental Wave and selected
unaudited 2004 pro-forma combined financial data
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DRAGON PHARMACEUTICAL INC.,
a Florida Corporation
Dated: April 5, 2005 /s/ Maggie Deng
----------------------------------------
Maggie Deng
Chief Operating Officer
EXHIBIT INDEX
Exhibit No. Description
99 Press release dated April 4, 2005 titled "Dragon
Pharmaceutical Announces Business Update after the
Completion of Acquisition of Oriental Wave and Selected
Unaudited 2004 Pro-forma Combined Financial Data "